ELTX Stock Analysis: Buy, Sell, or Hold?
ELTX - Elicio Therapeutics, Inc. Common Stock
$10.52
0.44 (4.32%)
▲
5d:
-0.33%
30d:
-24.02%
90d:
+31.44%
BUY
HIGH Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
ELTX is down 7.6% this week, but smart money is accumulating calls. Top strike: $15 2026-05-15 with 47 OI. Call ratio: 100% View Scanner →
Strength: 8.8/10
Get Alerted When ELTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ELTX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: ELTX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: ELTX is currently trading at $10.52, which is considered slightly low relative to its 30-day fair value range of $10.24 to $12.49.
Technical Outlook: Technically, ELTX is in a uptrend. Immediate support is located at $9.91, while resistance sits at $12.25. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $17.50 (+73.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ELTX is in a uptrend. Immediate support is located at $9.91, while resistance sits at $12.25. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $17.50 (+73.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$10.24 -
$12.49
Company Quality Score
55/100
(HOLD)
Options IV Signal
44th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 44th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.3%)
- BULLISH: Trading 73.6% below Wall St target ($17.50)
Fair Price Analysis
30-Day Fair Range
$10.24 -
$12.49
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$3.60
(34.2%)
Support & Resistance Levels
Support Level
$9.91
Resistance Level
$12.25
Current Trend
Uptrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.20
Wall Street Target
$17.50
(+73.6%)
Share & Embed Analysis
Last updated: March 31, 2026 3:04 PM ET
Data refreshes hourly during market hours. Next update: 4:04 PM
Data refreshes hourly during market hours. Next update: 4:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 59 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 59 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 54 HOLD |
